The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a significant substantial decrease in body mass and benefit metabolic functio